Mathkour Mansour, Banerjee Somdeb, Werner Cassidy, Hanna Joshua, Abou-Al-Shaar Hussam, Dindial Rishawn, Scullen Tyler, Boehm Lauren, Tubbs R Shane, Ware Marcus L
Ochsner Health System, Department of Neurosurgery, Ochsner Neuroscience Institute, Ochsner Clinic Foundation, New Orleans, LA, USA; Neurosurgery Division, Surgery Department, Jazan University, Jazan, Saudi Arabia.
Tulane Medical Center, Department of Neurosurgery, New Orleans, LA, USA.
Clin Neurol Neurosurg. 2021 Jan;200:106346. doi: 10.1016/j.clineuro.2020.106346. Epub 2020 Nov 2.
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor occurring supra- and infra-tentorially in both young adults and children. PXA is a benign tumor with a favorable prognosis. It is not traditionally considered as a neurofibromatosis type 1 (NF-1)-associated lesion, and its prognosis remains largely unknown, on the contrary to non-NF-1 PXA tumors.
Herein, we present a rare case of cerebellar PXA in a patient with NF-1 and performed systematic review of NF-1-associated PXA.
We present a case of NF-1-associated PXA arising in the cerebellar region. We also reviewed the literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines to identify published cases of cerebellar vs. non-cerebellar NF-1-associated PXA and NF1 vs. non-NF1 PXAs, highlighting their management paradigm, prognosis, and outcomes.
Our systematic review yielded only four previously reported cases of NF-1-associated PXAs in the cerebellar region. Our review suggests that infratentorial PXAs have a higher recurrence and lower survival rates than non-cerebellar NF-1-associated PXAs and non-NF1 PXAs in general.
Early and precise diagnosis is important for these lesions with the aid of imaging features, histology, immunohistochemistry, and genetic markers. Surgical resection with goal of GTR remains the mainstay management strategy for PXA, with adjuvant therapy usually reserved for anaplastic or malignant lesions. The identification of BRAF-V600E mutation and role of BRAF inhibitors hold promise as a diagnostic tool and treatment modality, respectively, for PXAs, and their relationship to NF-1 is worth further exploration.
多形性黄色星形细胞瘤(PXA)是一种罕见的脑肿瘤,可发生于年轻人和儿童的幕上及幕下区域。PXA是一种预后良好的良性肿瘤。传统上它不被视为1型神经纤维瘤病(NF-1)相关病变,并且与非NF-1的PXA肿瘤相反,其预后在很大程度上仍然未知。
在此,我们报告1例NF-1患者发生小脑PXA的罕见病例,并对NF-1相关的PXA进行系统评价。
我们报告1例起源于小脑区域的NF-1相关PXA病例。我们还根据系统评价和Meta分析的首选报告项目指南对文献进行了回顾,以确定已发表的小脑与非小脑NF-1相关PXA以及NF1与非NF1 PXA的病例,重点关注其治疗模式、预后和结果。
我们的系统评价仅发现4例先前报道的小脑区域NF-1相关PXA病例。我们的评价表明,幕下PXA总体上比非小脑NF-1相关PXA和非NF1 PXA具有更高的复发率和更低的生存率。
借助影像学特征、组织学、免疫组织化学和基因标志物对这些病变进行早期准确诊断很重要。以实现肿瘤全切除(GTR)为目标的手术切除仍然是PXA的主要治疗策略,辅助治疗通常仅用于间变性或恶性病变。BRAF-V600E突变的鉴定以及BRAF抑制剂的作用分别有望作为PXA的诊断工具和治疗方式,并且它们与NF-1的关系值得进一步探索。